By Leslie Carol Botha
(NaturalNews) Immunologist Charlotte Haug, MD PhD, MSc and Editor-in-Chief, Tidsskrift for Den norske legeforening (The Journal of the Norwegian Medical Association) raises an interesting question that has yet to be considered by the FDA, CDC or the medical community. What happens if other strains of HPV replace strains 16 or 18 after vaccination by Gardasil or Cervarix? If the vaccines are effective will the replacement viruses cause less disease or more disease?
SANE Vax Inc. is demanding Gardasil and Cervarix be taken off the market until these questions are answered in an independent study on HPV vaccine safety and efficacy.
Dr. Haug presented ‘To vaccinate or not – a different point of view’ at the 1st Nordic Gynecologic Meeting on HPV vaccination in March 2010 where she raised these questions. She stated that “Nature never leaves a void” and cited two studies that raise concern about viral replacement:
Alaska native children are experiencing replacement invasive pneumococcal disease just four years after vaccination (JAMA 2007)(1)
HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country (PubMed.gov)(2) Murillo et al 2009 revealed in this study that:
– Age-specific HPV type prevalence revealed significant differences
– Multiple high-risk infections appeared in 17% of the cases and represent a chance of replacement
– Highlight the role of HPVs other than 16/18 that will affect potential vaccine impact
Multiple high-risk infections appeared in 16.6% of cases and represent a chance of replacement. Age-specific HPV prevalence and multiple high-risk infections might influence vaccine impact. Both factors highlight the role of HPVs other than 16/18, which should be considered in cost-effectiveness analyses for potential vaccine impact.
A graph included in the above study – http://www.ncbi.nlm.nih.gov/pmc/art… – clearly shows that HPV 16 & 18 are not even prevalent in Colombian women until their mid-20s – long after vaccine efficacy has worn off if a girl is administered Gardasil or Cervarix in her adolescent years.
What are these vaccines doing? What are they effective against? And why are they on the market before these questions are answered?
SANE Vax, Inc. wants to remind medical consumers that viral replacement is not a new concept. The medical community is currently looking for ways to combat super-bacteria such as MRSA – (Methicillin-resistant Staphylococcus aureus) infection caused by a strain of staph bacteria that’s become resistant to the antibiotics commonly used to treat ordinary staph infections.(3)
When antibiotics were invented, no one understood bacterial and viral mechanisms of action; they have only one purpose – and that is to survive. Staph and strep bacteria mutated to survive in the suppressive environment created by the use, and abuse, of antibiotics. These ‘super-strains’ now pose a substantial risk to human survival in those exposed. Will the same thing happen as various strains of HPV in vaccines are suppressed?
The Colombian study raises another issue that needs to be addressed and that is whether HPV 16 & 18 are the dominant viral strains in the targeted demographic.
A May 2008 study on high-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women presented at the Second Annual International African-Caribbean Cancer Consortium Conference cited that:
The most important finding was that unlike the genotype distribution patterns seen in North America, Europe and some parts of Asia [11,12] HPV types 16 and 18 were not the most common high-risk genotypes. In our population, HPV types 45 and 58 accounted for 40.5% of the genotypes. Other groups, e.g. Trinidad and Tobago, Cuba and parts of Africa [13-18], have also reported different distributions of genotypes indicating that types 16 and 18 were not predominant in these populations. The recently developed prophylactic vaccines may therefore not be efficacious in our and similar populations.(4)
Why is Gardasil marketed globally through the Gardasil Access Program when HPV 16 & 18 may not even be prevalent amongst the targeted populations?(5)
The GARDASIL Access Program is pleased to announce that, following the November 2010 Advisory Board meeting, three new applicants were recommended for participation in the program. Since inception of the program, organizations and institutions in Bhutan, Bolivia, Cambodia, Cameroon, Georgia, Ghana, Haiti, Honduras, India, Kenya, Kiribati, Lesotho, Moldova, Nepal, Nicaragua, Nigeria, Papua New Guinea, Tanzania, Uganda, and Uzbekistan have been approved to receive more than 1 million doses of GARDASIL to gain operational experience in the design and implementation of HPV vaccination projects in their countries.
Interesting to note that Jamaica is not listed as one of the eligible countries for the Access Program? Is this because of the study?(6)
The conclusion of yet another study published in 2006, Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia states that infections with multiple HPV types seem to act synergistically in cervical carcinogenesis.(7)
Perhaps this is why the Vaccine Adverse Reaction System (VAERS) is beginning to report numerous cases of abnormal pap smears, genital warts, HPV infections and even cervical cancer post-HPV vaccination:
– 376 abnormal pap smears post HPV vaccination
– 108 reports of anogenital warts found after HPV vaccination
– 224 reports of papillomavirus infections found after HPV vaccination
– 41 reports of cervical cancer after HPV vaccination
Clearly there is a problem with the HPV vaccines – and it is the uninformed medical consumers who will suffer. Clearly, not enough studies have been conducted on the safety and efficacy of the HPV vaccines in targeting only two carcinogenic strains of HPV – that might not even be prevalent in many populations.
According to the CDC, “While there are well-established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed. More proximal measures of vaccine impact include outcomes such as prevalence of HPV vaccine types, incidence of cervical pre-cancers and genital warts.”(8)
SANE Vax, Inc. believes that there is no evidence to support the hypothesis that Gardasil or Cervarix effectively protects against cervical cancer. Indeed, the May 2006 FDA VRBPAC supports this conclusion by stating that if a woman is previously exposed to vaccine relevant HPV and is vaccinated anyway, her chances of getting cervical cancer increase 44.6% post Gardasil and 32.5% post Cervarix.(9)
1. Invasive Pneumococcal Caused by Nonvaccine Serotypes Among Alaska Native Children with High Levels of 7-Valent Pneumococcal Conjugate Vaccine Coverage, JAMA. 2007;297(16):1784-1792. doi: 10.1001/jama.297.16.1784 http://jama.ama-assn.org/content/29…
2. HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country, Infect Dis Obstet Gynecol. 2009;2009:653598. Epub 2009 Dec 20, http://www.ncbi.nlm.nih.gov/pubmed/…
3. MRSA Definition, Mayo Clinic, http://www.mayoclinic.com/health/mr…
4. High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women, Proceedings from the Second Annual International African-Caribbean Cancer Consortium Conference; Miami, FL USA 12–13 May 2008, http://www.ncbi.nlm.nih.gov/pmc/art…
5. Gardasil Access Program, http://gardasil-access-program.org/
6. Gardasil Access Program List of Eligible Countries, http://gardasil-access program.org/section/145
7. Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia, Cancer Epidemiology Biomarkers and Prevention, May 2006, http://cebp.aacrjournals.org/conten…
8. Post-licensure monitoring of HPV vaccine in the United States, Centers for Disease Control and Prevention, Vaccine. 2010 Jul 5;28(30):4731-7. Epub 2010 Feb 25, http://www.ncbi.nlm.nih.gov/pubmed/…
9. May 2006 VRBPAC Report, http://www.fda.gov/ohrms/dockets/ac…